Navigation Links
Genaera Liquidating Trust To Sell Remaining Proprietary Assets
Date:1/11/2010

SOUTHAMPTON, Pa., Jan. 11 /PRNewswire/ -- Argyce LLC, the trustee of the Genaera Liquidating Trust (the "Trust"), http://www.genaera.com, will divest the remaining drug development program assets of Genaera Corporation on an "as-is" basis. The Trust is soliciting bids to be received no later than February 12, 2010 for the assets, which may be purchased separately or in combination. Any person interested in purchasing the assets or learning more about the bidding process should contact the trustee's CEO, John Skolas.

The assets to be sold include the following:

  • IL-9 Antibody Licensor's Interest: AstraZeneca, through its subsidiary, MedImmune, Inc., is actively developing MEDI-528, a fully humanized monoclonal antibody to interleukin-9 ("IL-9"), as therapy for moderate to severe persistent asthma (collectively "the IL-9 program") and has announced its intention to proceed to a phase 2b trial. The Trust holds the licensor's interest formerly held by Genaera Corporation in the IL-9 antibody program, which includes rights to development and sales milestones and royalties on approved product sales; and
  • Pexiganan Acetate: Pexiganan is a novel, small peptide anti-infective, active against multi-drug resistant bacteria (MRSA, MDRAB), developed in a topical cream form. Pexiganan is the subject of an open IND and a pending New Drug Application ("NDA") for diabetic foot infection. In clinical trials conducted by Genaera, over 1,000 human subjects were exposed to pexiganan without safety concerns, including 418 patients who received pexiganan in two phase 3 clinical trials submitted in a NDA to the U.S. Food and Drug Administration in 1998.

Interested parties can obtain a copy of a non-confidential information package for each product along with a Confidential Disclosure Agreement ("CDA") by contacting John Skolas (trustee@genaera.com, phone 267-988-4079), Genaera Liquidating Trust, 610 Second Street Pike, Southampton, PA 18966. Following execution of the CDA, a confidential information package will be provided for each product.

The Genaera Liquidating Trust is managed by Argyce LLC, a boutique consulting and interim management firm focused on companies in transition - typically in early or late stages of a small company life cycle. Examples of such transitions include companies undergoing major management changes, start ups moving from incubator to operating stage, managed liquidations, liquidating trust services for life sciences companies and crises requiring creativity and stability.

ARGYCE serves small public companies and private equity/venture backed private companies. http://www.argyce.com .

SOURCE Genaera Liquidating Trust

RELATED LINKS
http://www.genaera.com

'/>"/>

SOURCE Genaera Liquidating Trust
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genaera Receives Non-Compliance Notice from Nasdaq
2. Genaera to Present at BIO-Europe 2008
3. Genaera Corporation Announces Second Quarter Financial Results
4. Genaera Corporation Elects Paul K. Wotton to Board of Directors
5. Genaera Corporation to Present at BIO Business Forum
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation Announces 2007 Financial Results
8. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
9. Genaera Corporation Announces Third Quarter Financial Results
10. Genaera to Present at Biotech 2007 and BIO InvestorForum
11. Genaera Elects New Board Member and Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):